🇺🇸 FDA

P0 · Therapeutic area intelligence

Neurology & CNS patent intelligence

Alzheimer's, Parkinson's, epilepsy, and CNS pharmaceutical patent landscape.

Patents
268

Quick answer

268 US pharmaceutical patents in our index match Neurology & CNS title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 10829536

    Methods of promoting CNS neuronal repair by inhibiting LRP-1

    The Regents of the University of California · Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10808247

    Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach

    Phio Pharmaceuticals Corp. · Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10800753

    Tetrahydrothiophene-based GABA aminotransferase inactivators and analogs thereof for treating neurological disorders

    Northwestern University · Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10799512

    Estrogen combination for treatment of multiple sclerosis

    The Regents of the University of California · Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10774121

    Methods and compositions for treating neurodegenerative disorders and Alzheimer's Disease and improving normal memory

    The Regents of the University of California · Granted Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10738361

    Methods of predicting clinical course and treating multiple sclerosis

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10653743

    Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10610535

    Diarylpropionitrile therapy for treatment of multiple sclerosis

    The Regents of the University of California · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10603311

    Use of pridopidine to improve cognitive function and for treating Alzheimer's disease

    The Board of Regents of the University of Texas System · Granted Tue Mar 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10562882

    Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10550157

    Compositions and methods for treating central nervous system (CNS) disorders and mood disorders

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10517853

    Methods for treating epilepsy

    PTC THERAPEUTICS, INC. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10456373

    Agent exhibiting anti-stress, anxiolytic and anti-depression activity, and composition based thereon

    OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU “NORMOFARM” · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10457670

    Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10450275

    Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain

    The Board of Regents of the University of Texas System · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10441580

    Iloperidone for the treatment of schizophrenia

    VANDA PHARMACEUTICALS INC. · Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10407495

    Bispecific antibody fragments for neurological disease proteins and methods of use

    ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10407374

    Compositions and methods for ameliorating CNS inflammation, psychosis, delirium, PTSD or PTSS

    The Regents of the University of California · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10363245

    Methods for treating CNS lesions

    The Board of Regents of the University of Texas System · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10357217

    Method for positron emission tomography (PET) imaging analysis for classifying and diagnosing of neurological diseases

    The Regents of the University of California · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10351589

    3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders

    Umecrine Cognition AB · Granted Tue Jul 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10336732

    1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders

    PGI Drug Discovery LLC · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10335466

    AADC polynucleotides for the treatment of parkinson's disease

    VOYAGER THERAPEUTICS, INC. · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10301393

    Methods of treating multiple sclerosis using anti-CD20 antibodies

    VACCINEX, INC. · Granted Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10265338

    Compounds and methods for treating neurological and cardiovascular conditions

    The Board of Regents of the University of Texas System · Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10233222

    Methods, compositions, diagnostics and assays for the treatment of Alzheimer's disease

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10221223

    Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory

    The Regents of the University of California · Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10206921

    Methods and compositions for treating a subject for central nervous system (CNS) injury

    The Regents of the University of California · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10188650

    Treatment of neurological disorders

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10183011

    Anti-depression compounds

    The Board of Regents of the University of Texas System · Granted Tue Jan 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10167314

    Methods of treating depression and other related diseases

    Northwestern University · Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10149853

    Stabilized formulations of CNS compounds

    Supernus Pharmaceuticals, Inc. · Granted Tue Dec 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10117907

    Glycosylated PACAP/VIP analogues with enhanced CNS penetration for treatment of neurodegenerative diseases

    Arizona Board of Regents on Behalf of the University of Arizona, a body corporate · Granted Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10098540

    Hyperspectral imaging for detection of Parkinson's disease

    Regents of the University of Minnesota · Granted Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10100367

    Diagnosing and monitoring CNS malignancies using microRNA

    The Regents of the University of California · Granted Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10071095

    1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders

    Addex Pharma, S.A. · Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10052363

    Mesenchymal stem cells for the treatment of CNS diseases

    BRAINSTORM CELL THERAPEUTICS LTD. · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9993449

    (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma

    Northwestern University · Granted Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9980931

    Use of glycyl glutamine against depression

    Uludag Universitesi Teknoloji Transfer Ofisi Ticaret Ve Sanayi Anonim Suirketi · Granted Tue May 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9957329

    Factor XII inhibitors for the treatment of neurological inflammatory disorders

    Julius-Maximilians-Universitat Wurzburg · Granted Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9868725

    Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimer's disease

    Takeda Pharmaceutical Company Limited · Granted Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9867830

    Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9855226

    d-methadone for the treatment of psychiatric symptoms

    Relmada Therapeutics, Inc. · Granted Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9856238

    1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders

    PGI Drug Discovery LLC · Granted Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9821023

    Methods for the treatment of central nervous system (CNS) disorders and mood disorders

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Nov 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9814755

    Methods for the treatment of depression and anxiety

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Nov 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9796755

    Methods of treating depression and other related diseases

    Northwestern University · Granted Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9789131

    Compounds and methods for treating neurological and cardiovascular conditions

    The Board of Regents of the University of Texas System · Granted Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Neurology & CNS patents are indexed?

268 patents match our Neurology & CNS classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.